心血管病学进展
心血管病學進展
심혈관병학진전
ADVANCES IN CARDIOVASCULAR DISEASES
2014年
5期
580-586
,共7页
刘维潮(综述)%陈化(审校)
劉維潮(綜述)%陳化(審校)
류유조(종술)%진화(심교)
达比加群%临床疗效%安全性
達比加群%臨床療效%安全性
체비가군%림상료효%안전성
dabigatran%clinical curative effect%safety
达比加群作为新型口服抗凝药，近年已被众多指南推荐为防治血栓栓塞性疾病或心房颤动且具有脑卒中风险的一线药物。相对于华法林，达比加群在临床疗效、患者依从性及安全性等方面具有更多优势。现就达比加群的临床疗效及安全性等方面的新近报道进行综述。
達比加群作為新型口服抗凝藥，近年已被衆多指南推薦為防治血栓栓塞性疾病或心房顫動且具有腦卒中風險的一線藥物。相對于華法林，達比加群在臨床療效、患者依從性及安全性等方麵具有更多優勢。現就達比加群的臨床療效及安全性等方麵的新近報道進行綜述。
체비가군작위신형구복항응약，근년이피음다지남추천위방치혈전전새성질병혹심방전동차구유뇌졸중풍험적일선약물。상대우화법림，체비가군재림상료효、환자의종성급안전성등방면구유경다우세。현취체비가군적림상료효급안전성등방면적신근보도진행종술。
The new oral anticoagulant dabigatran has been recommended as a first-line drug by many guidelines for the prevention and treatment of thromboembolic disorders or atrial fibrillation with high risk of stroke .Compared with warfarin , dabigatran has more advantages in clinical curative effect , and patient compliance and safety .The newly published efficacy and safety of dabigatran has been reviewed in this article.
